More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and strive to deliver superior business results. Mercury Pharmaceuticals thrives to maintain an environment built on mutual respect and individual integrity. This includes our customers we serve, employees, shareholders, partners, suppliers and communities.
Mercury Pharmaceuticals manufacturing solutions include contract biomanufacturing services, bioprocess development and purification equipment.
We have unique manufacturing capabilities and a track record for viruses and viral vectors (lentivirus, AAV, ADV, etc.) for gene therapy and vaccination, and experience in manufacturing monoclonal antibodies including: conjugation, mAb fragments and other rec-proteins from fermentation and cell culture for a broad range of therapeutic indications. We can also provide you with purification process development, along with preparative and industrial purification equipment for biologic and small biomolecule manufacturing including LPLC, continuous chromatography, and tailor-made TFF systems.
With history in traditional medicine, we have developed several drug products isolated from plant extracts.
We are always thriving to maintain on our core values at Mercury Pharmaceuticals, we embrace the principles of good corporate governance, implemented through strong, independent and diverse membership on our team. We are consistently implementing the best governance practices, it is more important than ever that we continually earn our investor's confidence. We will do this by remaining a leader in corporate governance and providing clear, consistent and truthful communication about our performance.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
31
Dec 2025
In a new study, Christine Agdestein has surveyed several aspects of the postnatal check-up. Agdestein is a specialist in general practice and a general practitioner, and is currently a PhD candidate at the Norwegian University of Science and Technology (NTNU). The research project is part of her PhD.
31
Dec 2025
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article published in Engineering titled "The Future of AI-Driven RNA Drug Development" by Yilin Yan, Tianyu Wu, Honglin Li, Yang Tang, and Feng Qian, explores how artificial intelligence (AI) can revolutionize RNA drug development, addressing current limitations and offering new opportunities for innovation.
31
Dec 2025
A recent study published in Engineering has shed light on the transmission and epidemiological trends of tmexCD1-toprJ1-positive Klebsiella pneumoniae across various ecological niches, highlighting the potential threat this antibiotic-resistant bacterium poses to global public health.
31
Dec 2025
Plastic pollution does more than litter landscapes and oceans. According to a new perspective article published in Biocontaminant, viruses living on plastic surfaces may play an underrecognized role in spreading antibiotic resistance, raising concerns for environmental and public health worldwide.